Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

PubWeight™: 3.43‹?› | Rank: Top 1%

🔗 View Article (PMID 24472190)

Published in Am J Transplant on February 01, 2014


M Haas1, B Sis, L C Racusen, K Solez, D Glotz, R B Colvin, M C R Castro, D S R David, E David-Neto, S M Bagnasco, L C Cendales, L D Cornell, A J Demetris, C B Drachenberg, C F Farver, A B Farris, I W Gibson, E Kraus, H Liapis, A Loupy, V Nickeleit, P Randhawa, E R Rodriguez, D Rush, R N Smith, C D Tan, W D Wallace, M Mengel, Banff meeting report writing committee

Author Affiliations

1: Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

Associated clinical trials:

Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation (DART) | NCT02424227

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch | NCT00275509

Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study | NCT03726307

The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant | NCT03965559

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA (PancDX) | NCT04166149

Articles citing this

(truncated to the top 100)

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ (2015) 2.11

Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol (2014) 1.78

Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2014) 1.60

IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J Clin Invest (2015) 1.51

Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant (2014) 1.49

Platelets in early antibody-mediated rejection of renal transplants. J Am Soc Nephrol (2014) 1.41

Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Front Immunol (2017) 1.39

Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant (2014) 1.29

IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol (2015) 1.07

The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective. J Am Soc Nephrol (2014) 1.01

Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol (2015) 1.00

Follicular T helper cells and humoral reactivity in kidney transplant patients. Clin Exp Immunol (2015) 0.96

Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol (2014) 0.96

Isolated endarteritis and kidney transplant survival: a multicenter collaborative study. J Am Soc Nephrol (2014) 0.94

Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. J Am Soc Nephrol (2015) 0.92

Central Role of CD45RA- Foxp3hi Memory Regulatory T Cells in Clinical Kidney Transplantation Tolerance. J Am Soc Nephrol (2015) 0.91

The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med (2015) 0.90

An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. Am J Transplant (2015) 0.89

Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant (2015) 0.88

IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4(+)T-cell responses. Sci Rep (2016) 0.87

Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol (2016) 0.85

Immune Monitoring as Prerequisite for Transplantation Tolerance Trials. Clin Exp Immunol (2017) 0.84

Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am J Transplant (2014) 0.84

Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection. J Am Soc Nephrol (2016) 0.84

Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study. J Am Soc Nephrol (2015) 0.83

The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. Kidney Int (2015) 0.83

Recent advances in renal transplantation: antibody-mediated rejection takes center stage. F1000Prime Rep (2015) 0.83

Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection. Clin J Am Soc Nephrol (2015) 0.83

Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol (2015) 0.82

Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation. Front Immunol (2015) 0.81

Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. J Am Soc Nephrol (2015) 0.81

Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens. J Am Soc Nephrol (2015) 0.81

What's new in clinical solid organ transplantation by 2013. World J Transplant (2014) 0.81

Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital images. Mod Pathol (2016) 0.81

Renal Biopsy in Type 2 Diabetic Patients. J Clin Med (2015) 0.80

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells? Front Immunol (2015) 0.80

MHC class I signaling: new functional perspectives for an old molecule. Tissue Antigens (2014) 0.80

Polyomaviruses and disease: is there more to know than viremia and viruria? Curr Opin Organ Transplant (2015) 0.80

T Follicular Helper Cells in Transplantation: The Target to Attenuate Antibody-Mediated Allogeneic Responses? Curr Transplant Rep (2015) 0.80

Vascular endothelium as a target of immune response in renal transplant rejection. Front Immunol (2014) 0.80

Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney Int (2015) 0.80

Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation. Am J Transplant (2014) 0.80

Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. Am J Transplant (2016) 0.80

Polyomavirus nephropathy: quantitative urinary polyomavirus-Haufen testing accurately predicts the degree of intrarenal viral disease. Transplantation (2015) 0.79

Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. Transpl Int (2015) 0.79

Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol (2016) 0.79

The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant (2016) 0.78

Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level. J Am Soc Nephrol (2016) 0.78

Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation. Front Immunol (2016) 0.78

Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. Am J Transplant (2015) 0.78

Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight (2016) 0.78

Markers of Endothelial-to-Mesenchymal Transition: Evidence for Antibody-Endothelium Interaction during Antibody-Mediated Rejection in Kidney Recipients. J Am Soc Nephrol (2015) 0.78

Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation. Eur J Clin Pharmacol (2015) 0.78

BK Polyomavirus and the Transplanted Kidney: Immunopathology and Therapeutic Approaches. Transplantation (2016) 0.78

Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies. Front Immunol (2016) 0.77

Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant (2014) 0.77

Clinical relevance of HLA antibody monitoring after kidney transplantation. J Immunol Res (2014) 0.77

NK Cells of Kidney Transplant Recipients Display an Activated Phenotype that Is Influenced by Immunosuppression and Pathological Staging. PLoS One (2015) 0.77

The Spectrum of Renal Allograft Failure. PLoS One (2016) 0.77

Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. Transplantation (2017) 0.77

Acute and chronic antibody-mediated rejection in pediatric kidney transplantation. Pediatr Nephrol (2014) 0.77

Exogenous Lipocalin 2 Ameliorates Acute Rejection in a Mouse Model of Renal Transplantation. Am J Transplant (2015) 0.77

Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transpl Int (2015) 0.77

Clinical and pathological features of kidney transplant patients with concurrent polyomavirus nephropathy and rejection-associated endarteritis. World J Transplant (2015) 0.77

The Use of Genomics and Pathway Analysis in Our Understanding and Prediction of Clinical Renal Transplant Injury. Transplantation (2016) 0.77

Expression of decoy receptor 3 in kidneys is associated with allograft survival after kidney transplant rejection. Sci Rep (2015) 0.77

Immunoglobulins: current understanding and future directions. Clin Exp Immunol (2014) 0.76

Proteomics for rejection diagnosis in renal transplant patients: Where are we now? World J Transplant (2016) 0.76

Tubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific Antibodies. J Am Soc Nephrol (2015) 0.76

Peritubular capillaritis in the renal allograft takes center stage. Kidney Int (2015) 0.76

Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 0.76

The Complement System and Antibody-Mediated Transplant Rejection. J Immunol (2015) 0.76

Infiltration of Macrophages Correlates with Severity of Allograft Rejection and Outcome in Human Kidney Transplantation. PLoS One (2016) 0.76

Benefits of a transfer clinic in adolescent and young adult kidney transplant patients. Can J Kidney Health Dis (2015) 0.76

Renal allograft rejection: pieces of the puzzle. J Am Soc Nephrol (2014) 0.75

Chronic antibody-mediated rejection: new diagnostic tools - clinical significance of C4d deposition and improved detection and characterization of human leucocyte antigen antibodies. Clin Exp Immunol (2014) 0.75

Expanding the antibody-mediated component of plasma cell-rich acute rejection: A case series. Indian J Nephrol (2016) 0.75

HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy. Medicine (Baltimore) (2016) 0.75

Intragraft Blood Dendritic Cell Antigen-1-Positive Myeloid Dendritic Cells Increase during BK Polyomavirus-Associated Nephropathy. J Am Soc Nephrol (2015) 0.75

Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression. Pediatr Nephrol (2014) 0.75

Natural Killer Cell Subsets and IL-2, IL-15, and IL-18 Genes Expressions in Chronic Kidney Allograft Dysfunction and Graft Function in Kidney Allograft Recipients. Int J Organ Transplant Med (2016) 0.75

Antibody-mediated vascular rejection of kidney allograft: characterization of different kidney allograft rejection phenotypes via histology, C4d deposition and donor-specific antibodies. Clin Exp Immunol (2014) 0.75

Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes. Kidney Int (2015) 0.75

Chronic active antibody mediated rejection associated with human leukocyte antigen-C*07 antibodies. Indian J Nephrol (2016) 0.75

Transplant glomerulopathy: the view from the other side of the basement membrane. J Am Soc Nephrol (2014) 0.75

The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients. J Renal Inj Prev (2016) 0.75

Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients. PLoS One (2016) 0.75

Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients. J Am Soc Nephrol (2015) 0.75

A Preliminary Study Into the Significance of Intrarenal Reflux in BK Virus Nephropathy After Kidney Transplantation. Transplant Direct (2016) 0.75

Multiparametric Functional MRI: Non-Invasive Imaging of Inflammation and Edema Formation after Kidney Transplantation in Mice. PLoS One (2016) 0.75

Many de novo donor-specific antibodies recognize β2 -microglobulin-free, but not intact HLA heterodimers. HLA (2016) 0.75

Evaluation of Renal Allograft Biopsies for Graft Dysfunction and Relevance of C4d Staining in Antibody Mediated Rejection. J Clin Diagn Res (2016) 0.75

Immunomodulatory Strategies Directed Toward Tolerance of Vascularized Composite Allografts. Transplantation (2015) 0.75

Transplant biopsy beyond light microscopy. BMC Nephrol (2015) 0.75

Plasma cell-rich acute rejection: A morphologic archetype of combined cellular and humoral rejection? Indian J Nephrol (2016) 0.75

Early Posttransplant Isolated v1 Lesion Does Not Need to Be Treated and Does Not Lead to Increased Fibrosis. Case Rep Transplant (2016) 0.75

Ongoing higher infection rate in ABO-incompatible kidney transplant recipient: is it a serious problem? A single-center experience. Ann Surg Treat Res (2016) 0.75

One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts. Clin Transplant (2015) 0.75

AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation. Am J Transplant (2014) 0.75

Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels. Transplant Direct (2015) 0.75

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09

Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA (1993) 5.21

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Liver transplantation (1). N Engl J Med (1989) 4.53

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43

Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr (1996) 3.42

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial. Lancet (1984) 3.11

International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int (1993) 3.11

Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol (2002) 3.05

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (2000) 2.94

Liver transplantation (2). N Engl J Med (1989) 2.93

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90

C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant (2006) 2.81

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest (2001) 2.79

Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab (2013) 2.63

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61

The morphology of "acute tubular necrosis" in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) (1979) 2.58

Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer (1971) 2.56

Recent declines in breast-feeding in the United States, 1984 through 1989. Pediatrics (1991) 2.53

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46

Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am J Clin Nutr (1993) 2.44

NEJ1 controls non-homologous end joining in Saccharomyces cerevisiae. Nature (2001) 2.42

Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med (1998) 2.40